Chronic Idiopathic Constipation Treatment Market Size Analysis, Industry Outlook, Regional Forecast 2021-2027

Precision Business Insights published a research report on "Chronic Idiopathic Constipation (CIC) Treatment Market : By Drug Class (Emollients, Laxatives, Bulk-forming agents, Chloride channel activators, Osmotic products, Others), By Route of Administration (Oral, Parenteral), By Distribution Mode (Prescription mode, Over-the-counter drugs), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies, Drug Stores) and Geography - Global/Region/Country Forecast to 2027".

Constipation is a disorder in which stool frequency drops to three times per week and stool passage becomes difficult. Constipation is a frequent functional gastrointestinal condition that can have a negative impact on a patient's life. The occurrence of persistent constipation problems with really no well-defined underlying issue is referred to as chronic idiopathic constipation. Irregular bowel motions, firm stools, straining during defecation, a sense of partial evacuation, bloating, and stomach pain, are all signs of chronic idiopathic constipation. Laboratory studies, endoscopy, radiographic examinations, magnetic resonance imaging, and physiological testing are used to identify chronic idiopathic constipation. For persistent idiopathic constipation, there are presently just a few authorized therapeutic options.

View Detailed Report Description here https://precisionbusinessinsights.com/market-reports/global-chronic-idiopathic-constipation-treatment-market/

Growing clinical studies and pharmaceutical company approval of drug candidates to meet unmet medical requirements of chronic idiopathic constipation therapy is a significant driver fueling market expansion during the forecast timeframe. For example, Shire plc obtained a new drug application from the US Food and Drug Administration in March 2018 for its drug candidate SHP555 (prucalopride) for the treatment of persistent idiopathic constipation in adults. Renexxion is also undertaking a phase 2 clinical study for Naronapride (ATI-7505), which is being developed for the treatment of a wide range of gastrointestinal diseases, including chronic idiopathic constipation. Ironwood and Allergan's Linzess (linaclotide) were authorized by the FDA in 2017 for the treatment of acute and chronic idiopathic constipation. Moreover, 50 percent of chronic constipation patients are unsatisfied with their present therapy, owing to ineffectiveness, highlighting the ongoing medical need for more effective and safer therapeutic treatments. Alternative therapies, such as home treatments and herbal medications, also including herbal laxatives, probiotic foods, and so on, are likely to be key roadblocks to market expansion.

The Global Chronic Idiopathic Constipation Treatment Market is segmented in terms of Distribution Channel, Drug, and Geography. In terms of Drug, the market is categorized into Laxatives, Osmotic Products, Chloride Channel Activators, and Others. The laxatives division is anticipated to expand at a significant pace during the forecast timeframe. In terms of Distribution Channel, the market is classified into Retail Pharmacies, Hospital Pharmacies, and Online sales. The hospital pharmacies division is categorized into expand at a substantial pace during the forecast timeframe.

The worldwide Chronic Idiopathic Constipation Treatment Market is dominated by North America. Due to the rising incidence of chronic idiopathic constipation amongst some of the senior population in the area, the region is expected to occupy a major share of the global Chronic Idiopathic Constipation Treatment Market throughout the forecast period. The high incidence of constipation and rising health-care spending in Asia Pacific, on the other hand, are projected to boost the Chronic Idiopathic Constipation Market in the forecast timeframe.

Request sample report https://precisionbusinessinsights.com/request-sample?product_id=17646

There are several industry players working in the chronic idiopathic constipation treatment market, which include GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Allergan Plc. (Ireland), Ironwood Pharmaceuticals, Inc. (U.S.), Astellas Pharma, Inc. (Japan), synergy pharmaceuticals, Inc. (U.S.), Sanofi S.A. (France), and Pfizer, Inc. (U.S.) to name a few.

Contact:
Mr. Satya
Precision Business InsightsTM | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 85278174

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.